DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE

DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE

Blockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists since 2010. During this period, the spectrum o...

Full description

Bibliographic Details
Main Authors: P. A. Shesternya, S. V. Prokopenko, E. Yu. Mozheiko, O. D. Gritsenko, T. V. Tupaeva, E. M. Kurts
Format: Article
Language:Russian
Published: IMA PRESS LLC 2019-09-01
Series:Научно-практическая ревматология
Subjects:
tocilizumab
rheumatoid arthritis
interleukin-6
adverse reaction
cognitive dysfunction
tofacitinib
Online Access:https://rsp.mediar-press.net/rsp/article/view/2764

Internet

https://rsp.mediar-press.net/rsp/article/view/2764

Similar Items